EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study

Overview of attention for article published in Radiotherapy & Oncology, April 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#26 of 5,051)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

twitter: 123 X users

reddit: 1 Redditor

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 26 Mendeley

Summary X Reddit Dimensions citations

So far, Altmetric has seen 137 X posts from 123 X users, with an upper bound of 220,254 followers.

RT @DrewMoghanaki: BREAKING: A new randomized trial demonstrates the benefit of SBRT for patients with EGFR+ stage IV NSCLC. It demonstrate…

15 Oct 2024

Reply Repost Favourite

RT @DrewMoghanaki: BREAKING: A new randomized trial demonstrates the benefit of SBRT for patients with EGFR+ stage IV NSCLC. It demonstrate…

14 Oct 2024

Reply Repost Favourite

“Radiotherapy of the primary lesion alone might be superior to metastatic sites.” https://t.co/zpPDmyL3hL

13 Oct 2024

Reply Repost Favourite

Combinaison SBRT & EGFR-TKIs de 1er et 2e génération stade IV Ph2 chinoise. 🔬vs Tki 📈 PFS 17.6 mois vs 9.0 mois. 📆 OS augmentée : 33.6 mois vs 23.2 mois. 🩺 Pas de toi grade 3 et +. Bénéfice supérieur si irradiation de la lésion primaire > Métastase

26 Aug 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 133 additional X posts.